Who
Diana Brainard
Director
Company insider
Files Form 4 as: Director, Nektar Therapeutics; Chief Executive Officer, Kalaris Therapeutics.
In numbers
- Trades disclosed
- 57
- Buys
- 1
- Sells
- 34
- Bought
- $107K
- Sold
- $676K
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 29 Jul 2020
- Last trade
- 23 Sep 2026
- Last filed
- 25 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Sep 2026filed 25 Sep 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,000 at $0.00 | filing |
| 23 Sep 2026filed 25 Sep 2026 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 23 Sep 2026filed 25 Sep 2026 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 23 Sep 2026filed 25 Sep 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,000 at $0.00 | filing |
| 30 Sep 2025filed 1 Oct 2025 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 19 Nov 2024filed 20 Nov 2024 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $4,7888,706 at $0.55 | filing |
| 5 Nov 2024filed 6 Nov 2024 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $9,12410,609 at $0.86 | filing |
| 21 Oct 2024filed 23 Oct 2024 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,6079,752 at $0.78 | filing |
| 3 Oct 2024filed 4 Oct 2024 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,2091,493 at $0.81 | filing |
| 18 Sep 2024filed 17 Jan 2025 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 20 Aug 2024filed 22 Aug 2024 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,9895,390 at $0.74 | filing |
| 19 Aug 2024filed 20 Aug 2024 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,3493,091 at $0.76 | filing |
| 5 Aug 2024filed 7 Aug 2024 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,91810,847 at $0.73 | filing |
| 19 Jul 2024filed 23 Jul 2024 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,2989,731 at $0.75 | filing |
| 2 Jul 2024filed 3 Jul 2024 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,0721,489 at $0.72 | filing |
| 21 May 2024filed 23 May 2024 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $4,0685,149 at $0.79 | filing |
| 17 May 2024filed 21 May 2024 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,3063,075 at $0.75 | filing |
| 3 May 2024filed 7 May 2024 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $8,19210,240 at $0.80 | filing |
| 19 Apr 2024filed 23 Apr 2024 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,2019,601 at $0.75 | filing |
| 2 Apr 2024filed 4 Apr 2024 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,1801,533 at $0.77 | filing |
News
No headline names them, or the companies they trade most, lately.